Management and Board
Per Jansson, D.D.S. Managing Director and Board member
Per has been involved with the medical industry for more than twenty years in leading positions. He has managed research based start-up companies to successful developments in both clinical and commercial terms. per-(d_)-_jansson-(_sm3Remove)-_-(_a)-_vicorepharma-(d_)-_comLena Mårtensson Lindblad, Ph.D., Assoc. Prof. Project Leader
Lena has a background in receptor pharmacology and has ten years of experience in product development in the biotech industry. She has initiated and coordinated extensive biological research programs and has recently been assigned the responsibility to coordinate the preclinical regulatory program in Vicore PharmaBjörn Dahlöf, M.D., Ph.D. Associate Professor of Cardiovascular Prevention
R & D Consultant
is an internist and a specialist in the cardiovascular area and holds long experience from clinical trials. Björn brings both pre-clinical and clinical expertise to Vicore Pharma together with an important network of academic collaboration and important high level pharma industry contacts. He has had an interest in the importance of the AT 2 receptor since more than 10 years.bjorn-(d_)-_dahlof-(_sm3Remove)-_-(_a)-_vicorepharma-(d_)-_com Göran Wessman
Göran is president and CEO of Mintage Scientific. He has more than thirty years of experience form the life science industry where his entrepreneurship has resulted in a number of successful and sustainable companies and ventures, e.g. Nobel Biocare (publ.), Boule Diagnostics and Carmel Pharma.goran-(d_)-_wessman-(_sm3Remove)-_-(_a)-_mintage-(d_)-_se Anders Ljunggren, B.Pharm.
Anders has been working with cardiovascular projects in the pharmaceutical industry for over 30 years. His main interest is the renin-angiotensin system with long experience from preclinical and clinical projects involving both ACE-inhibition and angiotensin receptor blockade.